Garuda - Garba Rujukan Digital

Implikasi Klinis Variasi Jumlah Copy Gen CYP2D6 Gayatri, Anggi; Ascobat, Purwantyastuti; Setiabudy, Rianto
Generics: Journal of Research in Pharmacy Vol 3, No 2 (2023): Generics: Journal of Research in Pharmacy, Volume 3, Edisi 2, 2023
Publisher : Faculty of Medicine, Diponegoro University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/halal.v%vi%i.19085

Enzim CYP2D6 adalah salah satu varian sitokrom P450 (CYP450) yang berperan dalam metabolisme obat di hati. Isoform ini berperan dalam memetabolisme 25% obat yang saat ini beredar di pasaran. Aktivitas CYP450 dapat dipengaruhi oleh berbagai faktor seperti usia, jenis kelamin, fungsi organ pemetabolisme, jenis dan derajat penyakit, serta variasi genetik. Salah satu faktor penentu aktivitas CYP2D6 adalah sifat gene CYP2D6 yang sangat polimorfik. Faktor penentu polimorfisme gen CYP2D6 adalah mutasi pada nukleotida tunggal (single nucleotide polymorphisms (SNPs)) dan variasi jumlah copy (copy number variation (CNV)) gen CYP2D6. Kejadian mutasi gen dan variasi jumlah copy gen CYP2D6 dapat meningkatkan atau menurunkan aktivitas enzim CYP2D6 yang selanjutnya dapat menurunkan atau meningkatkan efikasi obat yang merupakan substrat CYP2D6 ataupun dapat menimbulkan toksisitas obat. Berbagai penelitian telah dilakukan untuk mengevaluasi hubungan mutase SNPs gen CYP2D6 dengan efek obat. Dalam tinjauan kali ini akan dibahas mengenai pengaruh variasi jumlah copy (copy number variation) gen CYP2D6 terhadap efek terapi ataupun efek samping obat.

The effect of the BLUI blanket on the reduction of bilirubin levels in neonatal jaundice: a preliminary clinical study Fadilah, Tubagus Ferdi; Adisasmita, Asri C.; Ascobat, Purwantyastuti; Siswanto, Johanes Edy; Koestoer, Raldi Artono; Susianti, Yanti; Irwan, Hermansyah; Gunarsih, Arum; Heryana, Ade
Paediatrica Indonesiana Vol. 65 No. 3 (2025): May 2025
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14238/pi65.3.2025.245-52

Background Neonatal jaundice is a prevalent condition in newborns, characterized by elevated bilirubin levels. Conventional phototherapy treatments for neonatal jaundice typically require hospital admission, separation from mothers, and may interfere with breastfeeding and bonding. The Blue Light Universitas Indonesia (BLUI) LED phototherapy blanket was developed to address these limitations by providing a portable, home-based alternative that maintains mother-infant contact while delivering effective therapy. Objective To evaluate the efficacy of the Blue Light Universitas Indonesia (BLUI) LED phototherapy blanket in reducing bilirubin levels in infants with physiological jaundice. Methods A preliminary study was conducted from December 2022 to February 2023, involved 14 infants with physiological jaundice at Hermina Hospital Ciputat, Sariasih Hospital Ciputat, and the General Hospital of South Tangerang. The inclusion criteria were infants with physiological jaundice, gestational age ≥35 weeks, and birth weight ≥2,000 grams. The dependent variable was the reduction in total serum bilirubin levels, assessed by spectrophotometry. Paired sample T-test was used to compare bilirubin levels before and 24 hours after intervention with the BLUI Blanket. Results The study included 14 infants, with a mean age of 6.86 days and mean gestational age of 37.71 weeks. The BLUI Blanket demonstrated a mean bilirubin reduction of 3.11 mg/dL after 24 hours of continuous treatment, with a 19.02% decrease. The intervention was well-tolerated, with minimal adverse effects, such as maculopapular skin rash occurring in only one infant. Conclusion The BLUI Blanket is an effective and safe phototherapy device for reducing bilirubin levels in infants with physiological jaundice. This preliminary study supports further research to confirm these findings in larger populations.

Macronutrient Intake Among Multidrug-Resistant Tuberculosis Patients in Three Referral Hospitals in Indonesia Mariana, Nina; Gayatri, Anggi; Widyahening, Indah Suci; Rosdiana, Ano; Setiawaty, Vivi; Ascobat, Purwantyastuti
Indonesian Journal of Global Health Research Vol 7 No 5 (2025): Indonesian Journal of Global Health Research
Publisher : GLOBAL HEALTH SCIENCE GROUP

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37287/ijghr.v7i5.6624

Poor nutritional status, such as macro- and micronutrient deficiencies, might lead to worse clinical outcomes in multidrug-resistant tuberculosis (MDR-TB) patients. This study aimed to describe the macronutrient intake among MDR-TB patients and then compare those findings with the Indonesian recommended dietary allowance (RDA). A cross-sectional study of MDR-TB outpatients aged 18-65 years treated with the nine- or 18-month regimens at the end of the first month of treatment was conducted. Macronutrient intake data were obtained from a food consumption survey (24-hour food recall) of MDR-TB outpatients that was conducted by interviewing, recording, and then analyzing using NutriSurvey software, and compared with the RDA of the Ministry of Health of Indonesia. There were 63 outpatients with MDR-TB. The mean age was 38 (SD 12) years, and most of the patients were male (58.7%). Nutritional status based on BMI < 18,5 kg/m2 was observed in 43 patients (68.3%). According to the survey, after the end of the first month of MDR-TB treatment, the median (min–max) daily intake of energy was 1386.5 (519.4 – 2963.6) kcal per day, and the mean of protein was 49.6 (SD 23.0) grams per day. The median (min-max) daily intake of fat was 43.0 (1.1-170.6) grams per day, and the mean carbohydrate was 209.16 (87.9) grams per day. The proportions of energy, protein, fat, and carbohydrate deficiency were 85,7%, 68,8%, 74,6%, 90,5%, respectively. Macronutrient intake among MDR TB patients in this study was lower than the Indonesian recommended dietary allowance. These findings indicate that additional food intake and dietary counseling are needed in MDR-TB patients in Indonesia.

Implikasi Klinis Variasi Jumlah Copy Gen CYP2D6 Gayatri, Anggi; Ascobat, Purwantyastuti; Setiabudy, Rianto
Generics: Journal of Research in Pharmacy Vol 3, No 2 (2023): Generics: Journal of Research in Pharmacy, Volume 3, Edisi 2, 2023
Publisher : Faculty of Medicine, Diponegoro University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/halal.v%vi%i.19085

Enzim CYP2D6 adalah salah satu varian sitokrom P450 (CYP450) yang berperan dalam metabolisme obat di hati. Isoform ini berperan dalam memetabolisme 25% obat yang saat ini beredar di pasaran. Aktivitas CYP450 dapat dipengaruhi oleh berbagai faktor seperti usia, jenis kelamin, fungsi organ pemetabolisme, jenis dan derajat penyakit, serta variasi genetik. Salah satu faktor penentu aktivitas CYP2D6 adalah sifat gene CYP2D6 yang sangat polimorfik. Faktor penentu polimorfisme gen CYP2D6 adalah mutasi pada nukleotida tunggal (single nucleotide polymorphisms (SNPs)) dan variasi jumlah copy (copy number variation (CNV)) gen CYP2D6. Kejadian mutasi gen dan variasi jumlah copy gen CYP2D6 dapat meningkatkan atau menurunkan aktivitas enzim CYP2D6 yang selanjutnya dapat menurunkan atau meningkatkan efikasi obat yang merupakan substrat CYP2D6 ataupun dapat menimbulkan toksisitas obat. Berbagai penelitian telah dilakukan untuk mengevaluasi hubungan mutase SNPs gen CYP2D6 dengan efek obat. Dalam tinjauan kali ini akan dibahas mengenai pengaruh variasi jumlah copy (copy number variation) gen CYP2D6 terhadap efek terapi ataupun efek samping obat.

Title

Found 4 Documents
Search

Abstract

Abstract

Abstract

Abstract

Title Search

Found 4 Documents Search

Abstract

Abstract

Abstract

Abstract

Title

Found 4 Documents
Search